Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine (EDIT) reported Q3 2024 financial results, highlighting a net loss of $62.1 million ($0.75 per share). The company achieved preclinical proof of concept for in vivo HBG1/2 editing in HSPCs using proprietary targeted LNP technology for sickle cell disease and beta thalassemia treatment. Cash position stands at $265.1 million, expected to fund operations into Q2 2026. The company secured a $57 million upfront payment from DRI Healthcare Trust through the sale of certain future license fees. Research and development expenses increased to $47.6 million, while revenues decreased to $0.1 million.

Editas Medicine (Nasdaq: EDIT) announced significant progress towards its 2024 goals, including achieving in vivo preclinical proof of concept for hematopoietic stem and progenitor cell (HSPC) editing. The company utilized its proprietary targeted lipid nanoparticle (tLNP) to achieve a 29% editing level in HSPCs after a single dose, resulting in 20% HbF-expressing human red blood cells. This advancement is important for developing an in vivo treatment for sickle cell disease and beta thalassemia.

Editas also initiated a process to partner or out-license reni-cel, focusing resources on in vivo pipeline development. The company completed enrollment for the RUBY trial for severe sickle cell disease and the EdiTHAL trial for transfusion-dependent beta thalassemia. Additionally, Editas secured $57 million in non-dilutive capital through a sale agreement with DRI Healthcare Trust and ended Q3 2024 with approximately $265 million in cash and equivalents.

Editas Medicine (Nasdaq: EDIT) and Genevant Sciences have announced a collaboration and nonexclusive license agreement to develop in vivo gene editing medicines. The partnership will combine Editas' CRISPR Cas12a genome editing systems with Genevant's proprietary lipid nanoparticle (LNP) technology for two undisclosed targets in Editas' upregulation strategy.

Under the agreement, Genevant has granted Editas a nonexclusive worldwide license for certain LNP technology to develop mRNA-CRISPR Cas12a-LNP products. Genevant is eligible to receive up to $238 million in upfront and contingent milestone payments, as well as tiered royalties on future product sales.

This collaboration aims to advance Editas' vision of becoming a leader in in vivo programmable gene editing medicine, leveraging Genevant's expertise in LNP delivery systems, which have emerged as a preferred approach for delivering gene editing constructs.

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a strategic update webinar scheduled for Tuesday, October 22, 2024, at 8:00 a.m. ET. The webinar will focus on the company's progress towards its 2024 goals, including the significant achievement of establishing in vivo preclinical proof of concept.

The presentation will also cover business development and financial updates. Interested parties can access the live and archived webcast through a provided link or via the Events & Presentations page on the company's website. A replay of the webinar will be available in the Investors section of the Editas Medicine website following the conclusion of the event.

This strategic update offers an opportunity for stakeholders to gain insights into Editas Medicine's recent advancements and future directions in the field of gene editing.

Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.

The deal includes up to 100% of future annual license fees ranging from $5 million to $40 million per year and a mid-double-digit percentage of Editas Medicine's portion of a potential $50 million contingent upfront payment from Vertex. Editas Medicine retains rights to fixed annual license fees for 2024 and a mid-single-digit million-dollar payment upon Vertex achieving certain annual sales milestones.

This agreement follows Editas Medicine's December 2023 non-exclusive license to Vertex for Cas9 gene editing technology in sickle cell disease and beta thalassemia treatments, including CASGEVY®.

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced its participation in four upcoming investor conferences in September and October 2024. The company's management will engage in fireside chat discussions about Editas and its programs, including reni-cel.

The conferences include:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York
• 2024 Wells Fargo Healthcare Conference on September 5 in Boston
• 2024 Cantor Global Healthcare Conference on September 17 in New York
• Chardan 8th Annual Genetic Medicines Conference on October 1 in New York

Live webcasts of Editas Medicine's presentations will be available on the company's website, with archived replays accessible for approximately 30 days after each event.

Editas Medicine (Nasdaq: EDIT) reported its Q2 2024 results and provided business updates. The company is on track to present additional clinical data from the RUBY trial for sickle cell disease and the EdiTHAL trial for beta thalassemia by year-end. Editas also aims to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end.

Financial highlights include:

• Cash, cash equivalents, and marketable securities of $318.3 million as of June 30, 2024
• Net loss of $67.6 million, or $0.82 per share
• Research and development expenses increased to $54.2 million

The company expects its current financial position to fund operations into 2026.

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a conference call and webcast scheduled for August 7, 2024, at 8:00 a.m. ET. The event will cover the company's second quarter 2024 results and provide a corporate update. Interested parties can access the call via phone or webcast, with U.S. callers dialing +1-800-343-4849 and international callers using +1-203-518-9848. The webcast will be available on the company's website, and a replay will be accessible approximately one hour after the call concludes.

Editas Medicine has announced new safety and efficacy data for its gene-edited cell therapy, renizgamglogene autogedtemcel (reni-cel), from the RUBY trial, which included 18 patients with severe sickle cell disease (SCD). The data, presented at the European Hematology Association (EHA) Congress, shows that all patients treated with reni-cel experienced no vaso-occlusive events post-treatment, with follow-ups ranging up to 22.8 months.

Patients exhibited early normalization of total hemoglobin levels, averaging above 14 g/dL, and sustained improvements in fetal hemoglobin levels, exceeding 40%. The treatment was well-tolerated, with no serious adverse events reported. Editas has now dosed over 20 patients in the RUBY trial and completed adult cohort enrollment, with adolescent cohort enrollment underway.